UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~ Form 6-K

Report of Foreign Private Issuer ~~Pursuant to Rule 13a-16 or 15d-16~~

~~Under~~Pursuant to ~~the~~Rule ~~Securities~~13a-16 ~~Exchange~~or ~~Act of 1934~~15d-16

~~For~~ of the ~~Month~~Securities ofExchange ~~May~~Act ~~2026~~of 1934

~~001-36000~~For the ~~(Commission~~month ~~File~~of ~~Number)~~May 2026

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd.

(~~Exact name~~ Translation of ~~Registrant~~registrant’s asname ~~specified~~into ~~in its charter~~English)

26 Ben-Gurion St.

Ramat Gan,
5112001, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F or ☒ Form 40-F. ☐

~~Form 20-F ☒ Form 40-F ☐~~On May 22, XTL Biopharmaceuticals Ltd. issued the press release that is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

~~On Friday, May 15, 2026, XTL Biopharmaceuticals~~EXHIBIT Ltd. (the “Company”) announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, June 22, 2026 at 4:00 p.m. (Israel time) at the offices of the Company’s attorneys, Amit Pollack Matalon & Co.- Law Offices, at APM House, 18 Raoul Wallenberg St., Building D, Tel Aviv, Israel. In connection with the meeting, the Company furnishes the following documents:INDEX

1. A copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1; and

Exhibit No.		Description
99.1		Press Release dated May 22, 2026

2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2.

Exhibit Index

Exhibit No.		Description
99.1		Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders
99.2		Proxy Card for holders of ordinary shares with respect to the Company’s Extraordinary General Meeting of Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XTL BIOPHARMACEUTICALS LTD.
Date: Friday, May 15, 2026	/s/ Noam Band
Date: May 22, 2026	By:	/s/ Noam Band
	Noam Band Chief Executive Officer
		Noam Band
		Chief Executive Officer

Filing Compare · XTL BIOPHARMACEUTICALS LTD